Semax — the nootropic heptapeptide, explained
Semax is a synthetic heptapeptide developed at Moscow State University in the mid-1980s by the group of Ivan Ashmarin and colleagues as an analog of adrenocorticotropic hormone (ACTH) fragment 4-10. The molecule retains the behavioral effects of ACTH(4-10) fragments — memory, attention, neuroprotection — while removing the classical ACTH endocrine effects on the adrenal axis. Semax has been in clinical use in Russia since 1982 for indications including stroke, optic neuropathy, and cognitive disorders, but has not been approved by the FDA or any Western regulatory agency. It is one of the most studied compounds from the Russian peptide-research program that also produced Selank, cortexin, and the Khavinson peptide family. This primer covers the molecule, the mechanism, the Russian-heritage literature, and what research-context users should know.
The molecule. Semax is a heptapeptide with sequence Met-Glu-His-Phe-Pro-Gly-Pro. Molecular weight is 813.9 Da. The first four residues (Met-Glu-His-Phe) correspond to positions 4-7 of native ACTH — this is the neurotropic fragment. The added C-terminal Pro-Gly-Pro tripeptide was a deliberate design choice to confer resistance to peptidase degradation and extend the duration of action. Native ACTH(4-7) has a half-life of minutes; Semax retains activity for hours. The Pro-Gly-Pro motif is itself a minimal biologically active peptide with its own research literature (immunomodulatory effects, independent of the parent Semax molecule).
The Russian research heritage. Semax is a product of the Soviet-era peptide research program that emphasized short regulatory peptides as "minimal active fragments" of larger signaling proteins. The Ashmarin group's program at Moscow State University ran parallel to and predated much of the Western peptide-research boom. Semax has been in clinical use in Russia since 1982 — this gives it an unusual position in the peptide landscape: decades of clinical experience in one jurisdiction, virtually no Western regulatory footprint. The Russian clinical experience base is substantial but the evidence format (open-label, single-country, pre-modern-RCT) limits its weight in contemporary Western evidence-based-medicine frameworks.
Published literature — primary sources. The foundational modern review in English is Ashmarin IP, Nezavibatko VN, Levitskaya NG, Koshelev VB, Kamensky AA. Design and investigation of an ACTH(4-10) analog lacking D-amino acids and hydrophobic radicals. Neurosci Behav Physiol. 1995;25(4):339-348 — the Ashmarin group's own description of the Semax design rationale. For the BDNF-related mechanistic work, Dolotov OV, Karpenko EA, Seredenina TS, et al. Semax, an analog of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain. J Neurochem. 2006;97(Suppl 1):82-86 is the most-cited primary data on the BDNF-upregulation mechanism. For the stroke-research work, multiple Russian-journal publications exist but Western-indexed English coverage is thinner.
Proposed mechanisms. Three mechanistic strands run through the published literature: (1) BDNF upregulation — Semax administration has been shown to elevate brain-derived neurotrophic factor expression in rat basal forebrain, which is the current best-established mechanistic observation and the basis for the neuroprotective claims; (2) dopamine system modulation — Semax has effects on dopaminergic neurotransmission, particularly on D1/D2 balance in rodent models; (3) anti-inflammatory action in the brain — Semax reduces microglial activation in stroke models. The molecule is unusual in having multiple plausible mechanisms without a single dominant receptor target — it is not known to be a classical receptor agonist, and some published work proposes that Semax binds multiple low-affinity sites rather than one high-affinity receptor.
What's been studied. The rodent literature covers: stroke-model neuroprotection (focal ischemia, MCAO models), memory and attention paradigms (water maze, passive avoidance), optic neuropathy, and traumatic brain injury recovery. Russian clinical literature covers ischemic stroke (Semax is part of the approved Russian stroke-care protocol), diabetic neuropathy, glaucoma-related optic nerve damage, and some ADHD research. Independent Western clinical data is limited — there is no large Western-standard randomized controlled trial establishing Semax's effect on a hard clinical endpoint to contemporary pharmaceutical evidence standards.
Administration routes and dose ranges. Semax is most commonly administered intranasally — the molecule is designed for nasal bioavailability, which is unusual among research peptides and is a deliberate design choice from the Ashmarin program. The intranasal route delivers the peptide to the brain via the olfactory/trigeminal pathway, bypassing the blood-brain barrier. Published rodent and human doses via the intranasal route are typically 50-600 μg per administration, 1-3 times daily. Subcutaneous injection is a less common but documented route in research protocols, typically at higher absolute doses than intranasal due to systemic-first-pass differences. Vivaprime's Semax product is supplied in a format compatible with either route depending on the research protocol.
Storage, stability, and handling. Lyophilized Semax is stable at 2–8 °C for extended periods. Reconstituted solutions should be used within 30 days at 2–8 °C. The pen format's solvent system is stability-tested for in-use conditions. Semax is more heat-tolerant than the GLP-1-class peptides but less heat-tolerant than small peptides like epithalon. Do not freeze. Protect from light.
What the COA should say. A batch-specific COA for Semax should include (1) identity confirmation by HPLC-MS against the theoretical mass of 813.9 Da, (2) purity by reverse-phase HPLC-UV at 214 nm ≥ 98.0%, (3) residual solvent profile per ICH Q3C, (4) endotoxin by LAL in EU/mg. Sequence verification by amino acid analysis is a useful additional check — the Met-Glu-His-Phe N-terminus has several positional isomers that can co-elute on HPLC.
Research-use only. Vivaprime supplies Semax as research reference material for qualified researchers engaged in in-vitro laboratory work. Semax has not been approved by the FDA or any Western regulatory agency — its clinical history in Russia does not translate to Western regulatory approval. Nothing on this page constitutes a therapeutic, diagnostic, or consumption recommendation. The gap between Russian clinical experience and Western-standard evidence is wide; serious readers should evaluate the literature with awareness of the evidence-format difference. Purchasers affirm the research-use agreement at checkout.